Vaping High vs. Low Nicotine E-Liquid
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the 2 sites
- Trial code
- Status
- Withdrawn
- Started
- 1 Jun 2023
- Ended
- 31 Dec 2023
- Type of study
- Interventional, 2 groups
- Treatments tested
- Low Nicotine E-Liquid
- Medium or High Nicotine E-Liquid
- Record updated
- 22 August 2023
- Why it stopped
- Please see NCT04053868 for the current version of this study
Who can take part
- Age
- 21 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 51 criteriaShow less
Who can take part
- Healthy on the basis of medical history and limited physical examination, as described below:
- Heart rate < 105 beats per minute (BPM)*
- Systolic Blood Pressure < 160 and > 90*
- Diastolic Blood Pressure < 100 and > 50*; *Considered out of range if both machine and manual readings are above/below these thresholds
- Age: >= 21 years
- Age: <= 70 years
- Current regular user of open tank electronic cigarette (EC) (at least 20 times in the past 30 days) with e-liquid nicotine of 3-6 mg/mL
- Non-smoker or non-daily cigarette smokers agreeing to abstain from cigarettes for the duration of the study
- Saliva cotinine >50 ng/mL and/or NicAlert=6
- Carbon monoxide >= 5 ppm or per discretion of Principal Investigator
Who cannot take part
- Drug/Alcohol Dependence
- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
- Positive toxicology test for illicit drugs at the screening visit (THC \& prescribed medications okay)
- Opioid replacement therapy (including methadone, buprenorphine, or other)
- Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A6 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs)
- Concurrent use of nicotine-containing medications
- Concurrent participation in another clinical trial
- Concurrent regular use of marijuana (occasional users of these products may be enrolled if they agree to abstain from their use during the period of the study)
- Heart disease
- Seizures
- Cancer
- Thyroid disease (okay if controlled with medication)
- Diabetes
- Hepatitis B or C or Liver disease
- Kidney disease or urinary retention
- History of stroke
- An ulcer in the past year
- Active use of an inhaler for Asthma or Chronic obstructive pulmonary disease (COPD)
- Psychiatric conditions
- Current or past schizophrenia, and/or current or past bipolar disorder
- Major personality disorder
- Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the PI and considered for inclusion
- History of psychiatric hospitalizations is not exclusionary, but study participation will be determined as per PI's approval
- Psychiatric medications
- Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin-norepinephrine reuptake Inhibitors (SNRIs) and current evaluation by the PI that the participant is otherwise healthy, stable, and able to participate
- Use of sympatholytic medications for cardiovascular conditions including hypertension (Example: beta and alpha-blockers)
- Any stimulant medications (example: Adderall) generally given for attention deficit hyperactivity disorder (ADHD) treatment
- Other/Misc. Chronic Health Conditions
- Other "life threatening illnesses" as per PI's discretion
- Medical
- Glaucoma
- Major depression, current or within the past year
- Oral thrush
- Fainting (within the last 30 days)
- Pregnancy
- Pregnancy (self-reported and urine pregnancy test)
- Breastfeeding (determined by self-report)
- Inability to read and write in English
- Planning to quit vaping within the next 60 days
- Use of other tobacco products, smokeless tobacco, pipes, cigars/cigarillos, blunts/spliffs (no more than 10 times in the past month and must agree to abstain from their use during the period of the study)
Where in United States
- University of California San FranciscoSan Francisco, United States
- Zuckerberg San Francisco General HospitalSan Francisco, United States
About the trial
What the trial wants to find out
This study will examine the effects of electronic cigarette e-liquid nicotine content in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=36). The specific aim is to determine the impact of nicotine content of e-liquid on nicotine pharmacology, systemic exposure to toxic volatile organic compounds, and short-term cardiovascular effects.
The 2 groups in the trial
- Low NicotineOther group
Using an electronic cigarette, the patient will participate in a standardized vaping session using 3 mg/ml nicotine e-liquid.
Treatment: Low Nicotine E-Liquid
- Medium or High NicotineOther group
The patient will participate in a standardized vaping session using either an electronic cigarette with 18 mg/ml nicotine e-liquid or a JUUL device with a JUUL e-liquid pod.
Treatment: Medium or High Nicotine E-Liquid
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 22 August 2023